EXPERIENCE OF USING NEUROURIDINE® IN VARIOUS TYPES OF PERIPHERAL NEUROPATHY
DOI:
https://doi.org/10.31082/1728-452X-2020-217-218-7-8-29-36Keywords:
peripheral neuropathy, Neurouridine®, pain assessment, quality of lifeAbstract
The quality of life of patients with chronic pain syndrome remains one of the most pressing issues. Pain is considered chronic if it lasts or recurs for more than 3-6 months. This contributes to disability, depression, sleep disorders, poor quality of life, and what is important in this situation, the cost of treatment. According to statistics, the average prevalence of chronic pain in the adult population is 20%. Practitioners everywhere are in search of new methods of pain relief.
Purpose of research. The quality of life of patients with chronic pain syndrome has traditionally remained a topical issue. Given the permanent nature of pain and the completeness of approaches to its relief, the modern Clinician is constantly looking for new treatment methods that meet the principles of evidence-based medicine and safety.
Material and methods. This paper presents the results of using Neurouridine® in 30 patients with peripheral neuropathy. 30 patients were randomized for a 3-week treatment period. Average age: 47.5±1.5 years. All patients received standard symptomatic therapy, and an oral combination drug containing b vitamins, folic acid, choline, and Uridine was added to the treatment in the 150 mg mode once a day. Patients made three visits to the outpatient neurological office: visit 1-to evaluate pre-treatment, visit 2-after 10 days of treatment, and visit 3-after 20 days of treatment. Each patient was presented with two performance evaluations at each study visit: pain assessment on the CRS NRS scale, and the fps Face scale
Results and discussion. Analysis of the results of the treatment showed improvement in the form of reduced pain, improved quality of life in 65.90%, rapid recovery of performance in 32.10%, reduced need for analgesics in 59.90% and complete disappearance of symptoms in 25.30% of patients.
Pain was assessed using the HI NRG scale, the AZA Face scale, and the frequency of analgesics at the patient's first, second, and third visits.
Conclusion. The use of Neurouridine® for analgesic purposes has shown a positive effect on reducing symptoms in patients with peripheral neuropathy. The results confirm that this therapy provides a clear regeneration of the nerves, relieving pain, and reducing the soreness characteristic of nerve damage.
References
Treede R-D, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015;156(6):1003-7. DOI:10.1097/j.pain.0000000000000160
Palomo-Guerrero M, Cosgaya JM, Gella A, Casals N, Grijota-Martinez C. Uridine-5'-Triphosphate Partially Blocks Differentiation Signals and Favors a more Repair State in Cultured rat Schwann Cells. Neuroscience. 2018 Feb 21;372:255-265. DOI: 10.1016/j.neuroscience.2018.01.010. PMID: 29337237.
Kukushkin ML, Reshetnyak VK. Purinergic mechanisms of pain and analgesia. Zhurrossiiskii zhurnal boli = Russian Journal of Pain. 2019;17(1):51–56. (In Russ.). DOI:10.25731/RASP.2019.01.09.
Dedov II, Shestakova MV, Galstyan GR. Prevalence of type 2 diabetes in the adult population of Russia (nation study). Sakharnyi diabet = Diabetes mellitus. 2016;19(2):104-112. (In Russ.). DOI: https://doi.org/10.14341/dm2004116-17
Fonseca VA, Lavery LA, Thethi TK, Daoud Y, DeSouza C, Ovalle F, Denham DS, Bottiglieri T, Sheehan P, Rosenstock J. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013 Feb;126(2):141-9. DOI: 10.1016/j.amjmed.2012.06.022. PMID: 23218892
Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal. 2012;8(Suppl 1):3-26. DOI: 10.1007/s11302-011-9271-6
Lamarca A, Gella A, Martiañez T, et al. Uridine 5-triphosphate promotes in vitro schwannoma cell migration through matrix metalloproteinase-2 activation. PLoS One. 2014;9(6):e98998. DOI: 10.1371/journal.pone.0098998
Trippe BS, Barrentine LW, Curole MV, Tipa E. Nutritional management of patients with di- abetic peripheral neuropathy with Metanx: re- sults of a real-world patient experience trial. Сurr Med Res Opin. 2016;32(2):219-27. DOI: 10.1185/03007995.2015.1103215
Gareri Pietro, Castagna Alberto, Cotroneo Antonino Maria et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clinical interventions in aging. 3 Sep. 2015;10:1421-9. DOI: 10.2147/CIA.S87886
Magni G, Riccio D, Ceruti S. Tackling chronic pain and inflammation through the purinergic system. Current Medicinal Chemistry. 2018;25(32):3830–3865. DOI: 10.2174/0929867324666170710110630
Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(3):1-73. PMID: 28417449
Burnstock G. Purinergic Mechanisms and Pain. Adv Pharmacol. 2016;75:91-137. DOI: 10.1016/bs.apha.2015.09.001
Giniatullin R, Nistri A. Desensitization properties of P2X3 receptors shaping pain signaling. Front Cell Neurosci. 2013;7:245. DOI: 10.3389/fncel.2013.00245
Dunn PM, Zhong Y, Burnstock G. P2X receptors in peripheral neurons. Prog Neurobiol. 2001;65(2):107-134. DOI: 10.1016/s0301-0082(01)00005-3
Jaanus Suurveali, Boudinot Pierre, Kanellopoulos et al. P2X4: A fast and sensitive purinergic receptor. Biomed J. 2017;40(5):245-256. DOI: 10.1016/j.bj.2017.06.010
Negrao L, Almeida P, Alcino S, et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014;4(3):191–196. DOI: 10.2217/pmt.14.10
Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. Journal of Diabetes Investigation, 2017;8(5): 646-655, DOI: 10.1111/jdi.12650
Brown JJ, Pribesh SL, Baskette KG, Colberg SR. A Comparison of Screening Tools for the Early Detection of Peripheral Neuropathy in Adults with and without Type 2 Diabets. J Diabetes Res. 2017;2017(1):1-11. DOI: 10.1155/2017/1467213
Goldberg H, Mibielli MA, Nunes CP, et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res. 2017;10:397–404. DOI: 10.2147/JPR.S123045
Negrão L, Nunes P. Portuguese Group for the Study of Peripheral Neuropathy. Uridine monophosphate, folic acid and vitamin B12 in patients with symptomatic peripheral entrapment neuropathies. Pain Manag. 2016;6(1):25-9. DOI: 10.2217/pmt.15.60. PMID: 26679082
